Soren Gantt
Cited by
Cited by
Outcomes from pandemic influenza A H1N1 infection in recipients of solid-organ transplants: a multicentre cohort study
D Kumar, MG Michaels, MI Morris, M Green, RK Avery, C Liu, ...
The Lancet infectious diseases 10 (8), 521-526, 2010
Conservation of a gliding motility and cell invasion machinery in Apicomplexan parasites
S Kappe, T Bruderer, S Gantt, H Fujioka, V Nussenzweig, R Ménard
The Journal of cell biology 147 (5), 937-944, 1999
Proteasome Inhibitors Block Development ofPlasmodium spp
SM Gantt, JM Myung, MRS Briones, WD Li, EJ Corey, S Omura, ...
Antimicrobial agents and chemotherapy 42 (10), 2731-2738, 1998
Cost-effectiveness of universal and targeted newborn screening for congenital cytomegalovirus infection
S Gantt, F Dionne, FK Kozak, O Goshen, DM Goldfarb, AH Park, ...
JAMA pediatrics 170 (12), 1173-1180, 2016
Real-time detection and monitoring of loop mediated amplification (LAMP) reaction using self-quenching and de-quenching fluorogenic probes
VJ Gadkar, DM Goldfarb, S Gantt, PAG Tilley
Scientific reports 8 (1), 5548, 2018
Antibodies against Thrombospondin-Related Anonymous Protein Do Not Inhibit Plasmodium Sporozoite Infectivity In Vivo
S Gantt, C Persson, K Rose, AJ Birkett, R Abagyan, V Nussenzweig
Infection and immunity 68 (6), 3667-3673, 2000
Human herpesvirus 8-associated neoplasms: the roles of viral replication and antiviral treatment
S Gantt, C Casper
Current opinion in infectious diseases 24 (4), 295-301, 2011
Levels of circumsporozoite protein in the Plasmodium oocyst determine sporozoite morphology
V Thathy, H Fujioka, S Gantt, R Nussenzweig, V Nussenzweig, R Ménard
The EMBO journal, 2002
Myeloid derived suppressor cells are present at high frequency in neonates and suppress in vitro T cell responses
A Gervassi, N Lejarcegui, S Dross, A Jacobson, G Itaya, E Kidzeru, ...
PloS one 9 (9), e107816, 2014
The role of myeloid-derived suppressor cells in immune ontogeny
S Gantt, A Gervassi, H Jaspan, H Horton
Frontiers in immunology 5, 103650, 2014
The HIV protease inhibitor nelfinavir inhibits Kaposi's sarcoma-associated herpesvirus replication in vitro
S Gantt, J Carlsson, M Ikoma, E Gachelet, M Gray, AP Geballe, L Corey, ...
Antimicrobial agents and chemotherapy 55 (6), 2696-2703, 2011
Evaluation of mRNA-1273 vaccine in children 6 months to 5 years of age
EJ Anderson, CB Creech, V Berthaud, A Piramzadian, KA Johnson, ...
New England Journal of Medicine 387 (18), 1673-1687, 2022
Prospective characterization of the risk factors for transmission and symptoms of primary human herpesvirus infections among Ugandan infants
S Gantt, J Orem, EM Krantz, RA Morrow, S Selke, ML Huang, JT Schiffer, ...
The Journal of infectious diseases 214 (1), 36-44, 2016
Cell adhesion to a motif shared by the malaria circumsporozoite protein and thrombospondin is mediated by its glycosaminoglycan-binding region and not by CSVTCG
SM Gantt, P Clavijo, X Bai, JD Esko, P Sinnis
Journal of Biological Chemistry 272 (31), 19205-19213, 1997
Clinical presentation and outcome of epidemic Kaposi sarcoma in Ugandan children
S Gantt, A Kakuru, A Wald, V Walusansa, L Corey, C Casper, J Orem
Pediatric blood & cancer 54 (5), 670-674, 2010
Importance of COVID-19 vaccine efficacy in older age groups
M Sadarangani, BA Raya, JM Conway, SA Iyaniwura, RC Falcao, C Colijn, ...
Vaccine 39 (15), 2020-2023, 2021
Insights into the broad cellular effects of nelfinavir and the HIV protease inhibitors supporting their role in cancer treatment and prevention
S Gantt, C Casper, RF Ambinder
Current opinion in oncology 25 (5), 495-502, 2013
Intermittent preventive treatment using artemisinin‐based combination therapy reduces malaria morbidity among school‐aged children in Mali
B Barger, H Maiga, OB Traore, M Tekete, I Tembine, A Dara, ZI Traore, ...
Tropical Medicine & International Health 14 (7), 784-791, 2009
Transient oral human cytomegalovirus infections indicate inefficient viral spread from very few initially infected cells
BT Mayer, EM Krantz, D Swan, J Ferrenberg, K Simmons, S Selke, ...
Journal of virology 91 (12), 10.1128/jvi. 00380-17, 2017
Immunogenicity and safety of a tri-antigenic versus a mono-antigenic hepatitis B vaccine in adults (PROTECT): a randomised, double-blind, phase 3 trial
T Vesikari, JM Langley, N Segall, BJ Ward, C Cooper, G Poliquin, B Smith, ...
The Lancet Infectious Diseases 21 (9), 1271-1281, 2021
The system can't perform the operation now. Try again later.
Articles 1–20